BJA Advance Access published online on April 3, 2009
British Journal of Anaesthesia, doi:10.1093/bja/aep051
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
High-frequency jet ventilation for minimizing breathing-related liver motion during percutaneous radiofrequency ablation of multiple hepatic tumours


1 Institute of Anaesthesiology
2 Institute of Radiology, University Hospital Zurich, CH-8091 Zurich, Switzerland
* Corresponding author. E-mail: peter.biro{at}usz.ch
Movements of the liver caused by spontaneous breathing (during sedation or local anaesthesia) or by ventilation during anaesthesia are a source of concern in CT-guided procedures because of the limited spatial and contrast resolution of unenhanced imaging, artifacts caused by the probes and the relatively low temporal resolution of the fluoroscopy mode. During CT-guided radiofrequency ablation (RFA), it is essential that the lesion can be visualized optimally and that the ablation probe is positioned accurately to avoid non-target injuries. We therefore used high-frequency jet ventilation and general anaesthesia to minimize ventilation-related liver movement and provide optimal conditions for a patient undergoing RFA of hepatic metastases. The technical and anaesthetic considerations are discussed, and a specific limitation of transcutaneous PCO2 measurement during activation of the ablation is reported for the first time.
Keywords: ablation techniques; liver, neoplasms; surgery, hepatic; ventilation, high-frequency jet
Declaration of interest. P.B. has been involved in the development and design of the jet ventilation catheter used in this case and mentioned in this article. In the past 5 years, D.R.S. has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland; Alliance Pharmaceutical Corp., San Diego, CA, USA; AstraZeneca AG, Zug, Switzerland; Bayer (Schweiz) AG, Zürich, Switzerland; B. Braun Melsungen AG, Melsungen, Germany; CSL Behring GmbH, Hattersheim am Main, Germany; Fresenius SE, Bad Homburg v.d.H., Germany; Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland); GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany; Janssen-Cilag AG, Baar, Switzerland; Novo Nordisk A/S, Bagsvärd, Denmark; Octapharma AG, Lachen, Switzerland; Organon AG, Pfäffikon/SZ, Switzerland; and Roche Pharma (Schweiz) AG, Reinach, Switzerland.